I thought with all the discussion about using Actemra in GCA people might find this article interesting:
Actemra's patent is due to expire in the next few years and at least 3 companies are testing biosimilars - drugs that are near enough identical in action to the original substance. Other drugs that do much the same thing are close to market too - and while they will have to compete against fairly well-established Actemra, all these factors will put pressure on the companies to market their drugs at more competitive prices.
So, while it doesn't help us a lot at present, by 2022 there is likely to be a choice of drugs that would be effective in GCA and PMR and they are likely to be more reasonably priced. Though they will never be as cheap as corticosteroids...
We can live in hope.